Silo Pharma, Inc.
SILORating Trend
Earnings History
Next report: Dec 2, 2026 · EPS est. $-4.80| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.76 | $-0.32 | — | $18.0K |
| May 13, 2026 | $-1.80 | $-0.32 | $18.0K | $18.0K |
| Mar 27, 2026 | $-0.99 | — | $18.0K | — |
| Nov 13, 2025 | $-0.12 | $-0.20 | $18.0K | $18.0K |
| Aug 13, 2025 | $-0.19 | $-0.20 | $18.0K | $18.0K |
| May 9, 2025 | $-3.45 | $-0.21 | $18.0K | $18.0K |
| Mar 28, 2025 | $-0.41 | $-0.20 | $18.0K | $18.0K |
| Nov 12, 2024 | $-0.22 | $-0.21 | $18.0K | $18.0K |
News
Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software SARASOTA, FLA., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent subsidiary QwikAgents, today announced that QwikAgents has expanded its AI agent platform with new customer choice across both AI model…
Allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses SARASOTA, FLA., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application …
SARASOTA, FLA., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), ”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, today announced that company representatives will participate in the upcoming IPAC-RS 2026 Nasal Innovation Forum to be held September 16-17, 2026, in Jersey City, New Jersey.
InterCure (NASDAQ: INCR - Get Free Report) and Silo Pharma (NASDAQ: SILO - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk. Profitability This table compares InterCure and Silo Pharma's
Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program